Loading clinical trials...

Acupuncture for Anxiety/Depression in Patients With Breast Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Acupuncture for Anxiety/Depression in Patients With Breast Cancer

Effects of Acupuncture for Anxiety and/or Depression Among Patients With Breast Cancer

NCT07183813•Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Summary

The aim of this study is to evaluate the effects and safety of acupuncture on anxiety and/or depression among patients with breast cancer.

Eligibility

Age

18 - 70 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. Female, aged 18 to 70 years old;
•2. Meeting the diagnostic criteria for breast cancer and at TMN I-III;
•3. Having completed specialized active treatment for at least one month;
•4. With an ECOG score of 0-2;
•5. Mild to moderate anxiety and/or depression;
•6. Voluntarily joining this study and signing the informed consent form.

Exclusion Criteria

•1. Starting to take or change the regimen of anti-anxiety and/or -depression disorder medication within one month before enrolment;
•2. Received psychological intervention or physical therapy one month before enrolment or planning to use in the next 5 months;
•3. With diagnosis of anxiety and/or depression disorder prior to the diagnosis of breast cancer;
•4. Patients with suicidal tendencies, bipolar disorder and psychotic symptoms;
•5. Patients with severe anxiety and/or depression；
•6. Patients received acupuncture treatment within one month before enrolment;
•7. Participating in other clinical studies on the treatment of anxiety and/or depression;
•8. Combined with severe underlying diseases;
•9. Patients with severe skin ulcers;
•10. Pregnant or lactating patients;
+1 more criteria

Locations (1)

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Beijing, China

Key Dates

Start Date

September 15, 2025

Primary Completion Date

September 1, 2026

Completion Date

December 30, 2026

Last Updated

September 24, 2025

Enrollment

360

ESTIMATED participants

Conditions

Anxiety DepressionBreast CancerAcupuncture

Interventions

Electroacupuncture group

DEVICE

Sham electroacupuncture

DEVICE

Contacts

Yuanjie Sun

CONTACT

+8618810337542 puzhisun@163.com

Shuai Gao

CONTACT

+8613128205732 gaoshuai980314@163.com

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Acupuncture for Anxiety/Depression in Patients With Breast Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer